324 related articles for article (PubMed ID: 25544753)
1. Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma.
Derenzini E; Agostinelli C; Imbrogno E; Iacobucci I; Casadei B; Brighenti E; Righi S; Fuligni F; Ghelli Luserna Di Rorà A; Ferrari A; Martinelli G; Pileri S; Zinzani PL
Oncotarget; 2015 Mar; 6(9):6553-69. PubMed ID: 25544753
[TBL] [Abstract][Full Text] [Related]
2. DNA replication stress as an Achilles' heel of cancer.
Da-Rè C; Halazonetis TD
Oncotarget; 2015 Jan; 6(1):1-2. PubMed ID: 25595910
[No Abstract] [Full Text] [Related]
3. Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells.
Ferrao PT; Bukczynska EP; Johnstone RW; McArthur GA
Oncogene; 2012 Mar; 31(13):1661-72. PubMed ID: 21841818
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.
Restelli V; Chilà R; Lupi M; Rinaldi A; Kwee I; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Nov; 6(35):37229-40. PubMed ID: 26439697
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of CHK1 and WEE1 as a new therapeutic approach in diffuse large B cell lymphomas with MYC deregulation.
Restelli V; Vagni M; Arribas AJ; Bertoni F; Damia G; Carrassa L
Br J Haematol; 2018 Apr; 181(1):129-133. PubMed ID: 28025833
[No Abstract] [Full Text] [Related]
6. PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts.
Zhang C; Yan Z; Painter CL; Zhang Q; Chen E; Arango ME; Kuszpit K; Zasadny K; Hallin M; Hallin J; Wong A; Buckman D; Sun G; Qiu M; Anderes K; Christensen JG
Clin Cancer Res; 2009 Jul; 15(14):4630-40. PubMed ID: 19584159
[TBL] [Abstract][Full Text] [Related]
7. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
[TBL] [Abstract][Full Text] [Related]
8. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
9. Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma.
Rossi A; Orecchioni S; Falvo P; Tabanelli V; Baiardi E; Agostinelli C; Melle F; Motta G; Calleri A; Fiori S; Corsini C; Casadei B; Mazzara S; Vitolo U; Bertolini F; Zinzani PL; Alcalay M; Pelicci PG; Pileri S; Tarella C; Derenzini E
Leukemia; 2022 Jan; 36(1):197-209. PubMed ID: 34304248
[TBL] [Abstract][Full Text] [Related]
10. Reactive oxygen species mediate oridonin-induced apoptosis through DNA damage response and activation of JNK pathway in diffuse large B cell lymphoma.
Xu ZZ; Fu WB; Jin Z; Guo P; Wang WF; Li JM
Leuk Lymphoma; 2016; 57(4):888-98. PubMed ID: 26415087
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
Szydłowski M; Garbicz F; Jabłońska E; Górniak P; Komar D; Pyrzyńska B; Bojarczuk K; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Rymkiewicz G; Cybulska M; Statkiewicz M; Gajewska M; Mikula M; Gołas A; Domagała J; Winiarska M; Graczyk-Jarzynka A; Białopiotrowicz E; Polak A; Barankiewicz J; Puła B; Pawlak M; Nowis D; Golab J; Tomirotti AM; Brzózka K; Pacheco-Blanco M; Kupcova K; Green MR; Havranek O; Chapuy B; Juszczyński P
Cancer Res; 2021 Dec; 81(23):6029-6043. PubMed ID: 34625423
[TBL] [Abstract][Full Text] [Related]
12. Xanthatin triggers Chk1-mediated DNA damage response and destabilizes Cdc25C via lysosomal degradation in lung cancer cells.
Tao L; Cao Y; Wei Z; Jia Q; Yu S; Zhong J; Wang A; Woodgett JR; Lu Y
Toxicol Appl Pharmacol; 2017 Dec; 337():85-94. PubMed ID: 29074359
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.
Erdmann T; Klener P; Lynch JT; Grau M; Vočková P; Molinsky J; Tuskova D; Hudson K; Polanska UM; Grondine M; Mayo M; Dai B; Pfeifer M; Erdmann K; Schwammbach D; Zapukhlyak M; Staiger AM; Ott G; Berdel WE; Davies BR; Cruzalegui F; Trneny M; Lenz P; Barry ST; Lenz G
Blood; 2017 Jul; 130(3):310-322. PubMed ID: 28202458
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia.
Iacobucci I; Di Rorà AG; Falzacappa MV; Agostinelli C; Derenzini E; Ferrari A; Papayannidis C; Lonetti A; Righi S; Imbrogno E; Pomella S; Venturi C; Guadagnuolo V; Cattina F; Ottaviani E; Abbenante MC; Vitale A; Elia L; Russo D; Zinzani PL; Pileri S; Pelicci PG; Martinelli G
J Hematol Oncol; 2015 Nov; 8():125. PubMed ID: 26542114
[TBL] [Abstract][Full Text] [Related]
15. Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.
Bryant C; Rawlinson R; Massey AJ
BMC Cancer; 2014 Aug; 14():570. PubMed ID: 25104095
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition.
Meng F; Bhupathi D; Sun JD; Liu Q; Ahluwalia D; Wang Y; Matteucci MD; Hart CP
BMC Cancer; 2015 May; 15():422. PubMed ID: 25994202
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma.
Prince EW; Balakrishnan I; Shah M; Mulcahy Levy JM; Griesinger AM; Alimova I; Harris PS; Birks DK; Donson AM; Davidson N; Remke M; Taylor MD; Handler MH; Foreman NK; Venkataraman S; Vibhakar R
Oncotarget; 2016 Aug; 7(33):53881-53894. PubMed ID: 27449089
[TBL] [Abstract][Full Text] [Related]
18. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.
Gadhikar MA; Sciuto MR; Alves MV; Pickering CR; Osman AA; Neskey DM; Zhao M; Fitzgerald AL; Myers JN; Frederick MJ
Mol Cancer Ther; 2013 Sep; 12(9):1860-73. PubMed ID: 23839309
[TBL] [Abstract][Full Text] [Related]
19. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1.
Blasina A; Hallin J; Chen E; Arango ME; Kraynov E; Register J; Grant S; Ninkovic S; Chen P; Nichols T; O'Connor P; Anderes K
Mol Cancer Ther; 2008 Aug; 7(8):2394-404. PubMed ID: 18723486
[TBL] [Abstract][Full Text] [Related]
20. Targeting ubiquitin-activating enzyme induces ER stress-mediated apoptosis in B-cell lymphoma cells.
Best S; Hashiguchi T; Kittai A; Bruss N; Paiva C; Okada C; Liu T; Berger A; Danilov AV
Blood Adv; 2019 Jan; 3(1):51-62. PubMed ID: 30617217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
